



Synta Pharmaceuticals to Present at the Bear Stearns Boston Biotech Confab Conference

May 31, 2007

LEXINGTON, Mass.--(BUSINESS WIRE)--May 31, 2007--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, will be presenting at the Bear Stearns 3rd Annual Boston Biotech Confab Conference, at the Boston Marriott Copley Place on Thursday, June 7th at 1:40 p.m. (ET).

President and CEO, Safi Bahcall, Ph.D., will discuss data that will have been presented on Synta's lead drug compound, STA-4783, in metastatic melanoma at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 5, 2007 as well as development plans for the Synta oncology and inflammatory disease pipeline. The presentation will be broadcast live over the Internet. Those interested in listening to the live webcast should log on to the "Investors" section of Synta's website, www.syntapharma.com, prior to the event.

About STA-4783

STA-4783 is a novel, injectable, small molecule investigational drug candidate that induces a potent oxidative stress response in cancer cells, driving programmed cell death and enhancing the activity of anti-cancer agents that act through the mitochondrial apoptosis pathway, including paclitaxel. In September 2006, Synta reported positive Phase 2b results for STA-4783 in combination with paclitaxel in a double-blind, randomized, multi-center clinical trial in patients with stage IV metastatic melanoma. In November 2006, Synta received Fast Track designation from the FDA for the development of STA-4783 in metastatic melanoma. Synta plans to initiate a pivotal Phase 3 clinical trial for STA-4783 in mid-2007 and one or more Phase 2 studies in other cancer indications later in the year.

About Synta Pharmaceuticals

Synta Pharmaceuticals Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Synta has a unique chemical compound library, an integrated discovery engine, and a diverse pipeline of clinical- and preclinical-stage drug candidates with distinct mechanisms of action and novel chemical structures. The company's lead drug candidate, STA-4783, is an oxidative stress inducer which recently completed a double-blind, multi-center randomized Phase 2b clinical trial in metastatic melanoma and will be entering Phase 3 development in 2007. All Synta drug candidates were discovered and developed internally. For more information, please see www.syntapharma.com.

Safe Harbor Statement

This media release may contain forward-looking statements about Synta Pharmaceuticals Corp. Such forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described in Item 1A "Risk Factors" of our Annual Report on Form 10-K as filed with the Securities and Exchange Commission. Synta undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.

CONTACT: Synta Pharmaceuticals Corp.
Rob Kloppenburg, 781-541-7125
or
MacDougall Biomedical Communications
Doug MacDougall, 508-647-0209

SOURCE: Synta Pharmaceuticals Corp.